Plasmids. cDNA fragments containing the reading frames of ERG and TRIM25 were amplified by PCR using primers appended with restriction site sequences and cloned into the pCMV-TnT vector (Promega) or pIRESneo3 (Promega) that had been modified with a C-terminal V5, HA or 3xFlag tag or into the pGEX6P-2 vector (GE Healthcare Life Sciences). ERG-ΔN39, ERG-ΔN99, ERG-ΔNAD, ERG-ΔPNT, ERG-ΔM, ERG-ΔETS, ERG-ΔCAD, TRIM25-ΔRING, TRIM25-ΔCCD and TRIM25-ΔSPRY were subcloned into pCMV-TNT vector with V5 or 3xFLAG tag. pRK5-HA-Ubiquitin was obtained from Addgene. All primer sequences are listed in Supplementary Table 2. RNAi reagents. Endoribonuclease-prepared siRNAs (esiRNA) were prepared as previously described (Kittler et al., 2005; Kittler et al., 2004; Kittler et al., 2007) . In brief, esiRNA target regions that were predicted in silico to produce the most specific and efficient esiRNAs were amplified from a human cDNA library with primers appended with T7 RNA polymerase promoter sequence. The PCR products were used for in vitro transcription of RNA with T7 polymerase, followed by denaturation and annealing to generate long double-stranded RNA, which was digested with GST-RNase III to esiRNAs of 19-25 bp, which were then purified by ion exchange chromatography and isopropanol precipitation. Chemically synthesized ON-TARGET plus siRNAs were obtained from Dharmacon. All esiRNA primer sequences and siRNA sequences are listed in Supplementary Table 2. 
Signaling Technology, 3724), V5 (Bethyl Laboratories, A190-120A), ERG (Epitomics, 2805, or Santa Cruz, sc-271048) , GAPDH (Cell Signaling Technology, 2118), Flag M2 (Sigma, F3165) and β-actin (Cell Signaling Technology, 4970); Immunohistochemistry: TRIM25 (Abcam, ab167154), ERG (Biocare Medical, CM421). The following reagents were used: cycloheximide (Sigma); Ubiquitin Activating Enzyme (UBE1) (BostonBiochem, E-305), UbcH5a/UBE2D1 (BostonBiochem, E-616), HA-Ubiquitin (BostonBiochem, U-110), 6xHis-Ubiquitin (BostonBiochem, U-530), 6xHis-Ubiquitin K48 (BostonBiochem, UM-HK480) and 6xHis-Ubiquitin K63 (BostonBiochem, UM-HK630), V5 peptide (Sigma, V7754).
ERG immunoprecipitation and Mass spectrometry. ERG-V5 was transiently expressed in
HEK293T cells by transfection with the pCMV-ERG-V5 expression vector. 48 hours after transfection, cells were lysed (lysis buffer: 25mM HEPES [pH7.5], 400 mM NaCl, 0.5% IGEPAL CA-630, 1mM DTT, 5% glycerol and protease inhibitors). The soluble fraction of the lysate was diluted to adjust the NaCl concentration and IGEPAL CA-630 concentration to 100 mM and 0.125%, respectively, and then pre-cleared with GammaBind G Sepharose (GE Healthcare). Pre-cleared lysates were incubated with a mouse anti-V5 antibody (Genscript, A01724) at 4°C for 3 hours, followed by immunoprecipitation with GammaBind G Sepharose beads at 4°C for 1 hour. Then beads were washed four times with 100 mM NaCl and 0.1% IGEPAL CA-630. Proteins were eluted with V5 peptide (500 ng/ml) at 4°C for 30 minutes. The eluted fraction was mixed with 2X Laemmli buffer and boiled for subsequent SDS-PAGE. For mass spectrometry, PAGE gel slices with bands of interest were digested with trypsin and desalted with C18 ZipTips (Millipore) according to the manufacturer's instructions. An integrated system that includes an Agilent 1100 series Nanoflow LC system (Agilent) and a LTQ 2D trap mass spectrometer (Thermo Electron) equipped with a nanoelectrospray ionization (NSI) source was used to perform high performance liquid chromatography tandem mass spectrometry (HPLC/MS/MS) analysis: Tryptic peptides were separated by a capillary HPLC column packed in-house with Luna C18 resin (Phenomenex). The eluted peptides were directly electrosprayed into the LTQ ion trap mass spectrometer, with a data-dependent mode. Mascot (version 2.3, Matrix Science) database was used to map peptides to proteins. Protein purification and GST Pulldown. GST-TRIM25 protein and GST-TRIM25-ΔRING were expressed in E. coli BL21(DE3) after transformation of the pGEX6P-2 expression vector.
After induction for 5 hours with 0.4 mM IPTG at 32°C, bacteria were pelleted by centrifugation.
The pellets were resuspended in lysis buffer (10 mM Na 2 HPO 4 , 1.8 mM KH 2 PO 4 , [pH 7.4], 300 mM NaCl, 2.7 mM KCl, 0.5% Triton X-100, 5% glycerol, 1 mg/ml Lysozyme, 1 mM PMSF, 2 mM DTT). After incubating the resuspended cells on ice for 1 hour, lysis was performed by sonication, and the lysate was cleared by centrifugation. Glutathione sepharose 4B beads (GE Healthcare) were added to the supernatant and incubated with gentle agitation at 4°C for 2 hours.
The beads were washed four times with lysis buffer. Then, GST-fusion proteins were eluted with 10 mM glutathione and stored at -80°C. Pre-cleared lysates were incubated with V5, FLAG or HA antibodies at 4°C for 3 hours, followed by immunoprecipitation to the sepharose beads at 4°C for 1 hour. Beads were washed four times with 100 mM NaCl and 0.1% IGEPAL CA-630, boiled in Laemmli buffer for Western blot analysis. Biochem) and HA-ubiquitin (10 µg; Boston Biochem). The mixtures were incubated at 32°C for 2 h and subjected to immunoblotting with anti-V5 antibody (Bethyl Laboratories).
Construction of the
To obtain purified USP9X and USP9X catalytically inactive mutant proteins, plasmids encoding Flag-tagged wildtype USP9X and USP9X C1566S-mutant were transfected into HEK293T cells for 48 hours. The cells were lysed in USP9X lysis buffer (50mM HEPES [pH7.5], 300 mM NaCl, 0.2% Triton X-100, 1mM DTT, 5% glycerol) without protease inhibitor, and cell lysates were immunoprecipitated with anti-Flag M2 affinity gel (Sigma) for 3h at 4 °C and eluted with Flag buffer (50mM HEPES [pH7.5], 300 mM NaCl, 1mM DTT, 5% glycerol and 500 µg/ml Flag peptide). Eluted protein was then dialyzed overnight against DUB buffer (50mM HEPES (pH7.5), 100 mM NaCl, 1mM DTT, 5% glycerol). Activity of USP9X-wt-Flag and USP9X-C1566S-Flag was measured using the fluorometric AMC-ubiquitin assay (BostonBiochem) with a fluorometer (Hitachi). For the combined in vitro ubiquitination/deubiquitination assay, purified USP9X-wt-Flag, USP9X-C1566S-Flag or mock were pre-treated with 10 mM DTT for 15 minutes at room temperature, and subsequently incubated in the reaction for ERG ubiquitination by GST-TRIM25 as described above.
Immunohistochemical staining
Immunohistochemical staining was performed as previously described (Strand, 2012; Ma, 2010) .
Briefly, 5 µm sections were deparaffinized, rehydrated and endogenous peroxidases were blocked with 2% hydrogen peroxide in methanol. Sections were then boiled in citrate for antigen retrieval and blocked in 2.5% horse serum for 1 hour. Primary antibodies were incubated at 4°C overnight: ERG (1:100, Biocare medical) and TRIM25 (1:100, Abcam). Biotinylated horse antirabbit and horse anti-mouse secondary antibodies (1:500, DAKO Carpentaria) were incubated for 60 minutes at room temperature. Slides where incubated in ABC reagent conjugated with horseradish peroxidase (Vector Laboratories Burlingame) for 30 minutes. Finally, staining was visualized by 3, 3'-diaminobenzidine tetrahydrochloride (DAB substrate) and counterstained with hematoxylin QS (Vector Laboratories Burlingame).
Immunohistochemical analysis and scoring
Tumor cells with ERG staining and/or TRIM25 staining were evaluated manually for each tissue core by a reviewer who was blinded to the clinical data. ERG and TRIM25 protein expression levles were registered semi-quantitatively as follows: Staining intensity (0, no staining; 1, weak staining; 2, moderate staining; and 3, intense staining) and the proportion of stained cells (0, no staining; 1, 1-25% staining; 2, 26-50%; 3, 51-75%; and 4, if more than 75% of the tumor cells were positive.
Analysis of RNA-seq data. RNA-seq data for prostate adenocarcinoma primary tumor samples was retrieved from TCGA database (N=498). The tags per million (TPM) values for ERG and TRIM25 genes were converted to FPKM values and samples that have ERG expression greater than 25 were selected (N=193). A concordance plot was generated using ERG and TRIM25
expression from the selected 193 ERG-positive tumors.
Analysis of ERG occupancy at the TRIM25 gene promoter. ERG ChIP-seq reads generated for VCaP cells was retrieved from NCBI GEO (GSE14092). SRA files were converted to fastq files and mapped to hg19 using bowtie (v.2.2.5). Bigwig files were generated from uniquely 
